Compass Therapeutics, Inc. (CMPX)
NasdaqCM · USD · Healthcare · Biotechnology
$0.7472 (-1.81%) as of
Key statistics
- Market cap
- 134.56M
- Forward P/E
- -1.39
- EPS (TTM)
- -0.3900
- Dividend yield
- 0.00%
- 52-week range
- 0.7410 – 6.8800
- Beta
- 0.91
- Profit margin
- 0.00%
- Analyst target
- $5.45
- Volume
- 2.21M
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 39
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.